Indonesia Growth Platform — Operational Update: GENRÊVER CLINIC Jakarta, INVITRX and PARVA
Detailed companion to the Company’s press release of September 4, 2026 — a follow-up to the July 29, July 30 and August 10, 2026 announcements
Key Facts
- Company
- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC.
- Ticker
- Nasdaq: BIOT
- Announcement Date
- Category
- NEWS
- Source
- Official BIOT announcement
Tokyo, Japan – September 4, 2026
INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) (“Instinct Bio” or the “Company”) today issued a press release providing an operational update on its three Indonesia-related initiatives. Because a wire release must be brief, this page provides the fuller picture: what has been done since each announcement, what each initiative is designed to achieve, and what the next steps are. The press release remains the official summary; where this page adds context, it draws only on facts the Company has previously disclosed.
The Indonesia platform at a glance
The three initiatives announced in July and August 2026 are designed to work as one platform. Each plays a distinct role:
Sell
GENRÊVER CLINIC
Announced July 29, 2026. Indonesia’s first subscription-model beauty clinics under the Company’s own Japanese brand. The customer-facing front of the platform.
Advance
INVITRX collaboration
Announced July 30, 2026. GENRÊVER cosmetics manufactured in the United States at INVITRX’s facility using INVITRX ingredients and sold in the U.S. market — plus co-development of clinic-based cell processing capabilities in Indonesia.
Make
PARVA collaboration
Announced August 10, 2026. Local manufacturing of GENRÊVER and HAKUA cosmetics in Indonesia, drawing on the Company’s Japanese formulation expertise.
Underpinning all three are the Company’s two brands, GENRÊVER and HAKUA, and approximately six years of commercial relationships in the region — including the Company’s long-standing ingredient sourcing relationship with INVITRX.
1. GENRÊVER CLINIC — Jakarta flagship
What has happened since July 29
The Company has secured a 213 m² premises in the Gandaria district of South Jakarta for its first planned GENRÊVER CLINIC site, and interior construction has commenced. Subject to construction progress, permitting and operational readiness, the Company is targeting an opening by the end of December 2026.
213 m²
Premises secured in Gandaria, South Jakarta
Dec 2026
Targeted opening (subject to conditions)
3 tiers
Preliminary monthly subscription pricing
5 cities
Planned network: Jakarta, Surabaya, Bandung, Medan, Bali
The subscription model
As announced on July 29, GENRÊVER CLINIC is designed as a subscription-model clinic: members pay a fixed monthly fee, may cancel at any time, and see transparent pricing — a deliberate departure from the pre-paid package model common in the market. The Company has now finalized preliminary pricing at three monthly tiers:
Tier — Monthly rate (per customer) — Notes
Tier 1 — US$400 — Membership contents by tier will be announced ahead of opening. Treatment availability is subject to membership terms, physician assessment, scheduling capacity and applicable regulatory requirements. Pricing is preliminary and may change.
Tier 2 — US$1,000
Tier 3 — US$3,000
The clinic will be accompanied by a Japanese-style café (matcha and bakery), forming part of the brand experience. Operations are conducted through the Company’s Indonesian entity (PT PMA), with medical supervision and regulatory matters handled in partnership with Dr. Mario Damianus Daniel Hadinoto, as previously disclosed.
From one clinic to a network
Jakarta is the flagship and proving ground. The July 29 announcement set out a five-city plan — Jakarta, followed by Surabaya, Bandung, Medan and Bali — with an initial investment of approximately US$1 million, to be expanded on a phase-gate basis: each subsequent clinic is funded from the cash flow of the clinics before it, rather than from a large up-front commitment. This is the discipline the Company intends to keep as the network grows.
Why Indonesia, and why a clinic
As disclosed on July 29, Indonesia’s medical aesthetics market was estimated at approximately US$260 million in 2023 and is projected by third-party research to reach approximately US$500 million by 2029 (a compound annual growth rate of about 11.5%), supported by an upper-middle-income population of roughly 40 million people. The clinic is also positioned as a gateway: a physical, regulated setting in which the Company can, subject to applicable approvals, introduce regenerative-medicine-related services over time.
Market figures are third-party estimates cited in the Company’s July 29, 2026 announcement and are not Company forecasts.
2. INVITRX — Make in the U.S., sell in the U.S.
The Company and INVITRX have identified an initial GENRÊVER-branded cosmetic product line-up for potential manufacture in the United States. The products are made at INVITRX’s U.S. GMP-certified facility, using INVITRX’s ingredients under the Company’s formulations, and sold in the U.S. market as premium Japanese-origin cosmetics — not exported from Japan. Manufacturing is currently targeted to commence within 2026, subject to final formulation, manufacturing scheduling, regulatory considerations and related commercial arrangements. Under the same July 30 agreement, the parties also intend to co-develop clinic-based cell processing capabilities alongside GENRÊVER CLINIC in Indonesia, subject to regulatory approval.
A full update on the U.S. business — how the model works, why the Company manufactures in the United States, and the project status table — is published as a separate article: INVITRX Collaboration Update: GENRÊVER — Made in the U.S., Sold in the U.S. — [link].
3. PARVA — Made in Indonesia, powered by Japanese formulation expertise
The Company and PARVA have identified two initial cosmetic product candidates for the Indonesian market under the GENRÊVER and HAKUA brands: a premium UV cream and a moisturizing gel incorporating HA4 low-molecular-weight hyaluronic acid technology. Production is targeted to commence within 2026, subject to product development completion, regulatory compliance and manufacturing readiness.
A full product development update — why UV care was chosen first, the formulation approach, the regulatory pathway including halal certification, and the project status table — is published as a separate article: Product Development Progress Update: Indonesia Cosmetics Collaboration with PT PARVA CANDELA — [link].
Why Indonesia: the market context
Indonesia is home to approximately 280 million people and the world’s largest Muslim population. From October 17, 2026, halal certification becomes mandatory for cosmetics sold in Indonesia. The Company intends to develop and manufacture halal-certified skincare under its own brands — meeting the domestic requirement while creating a basis for potential export to neighboring ASEAN markets (population approximately 680 million) and other Muslim-majority markets, subject to halal, CPKB (Indonesian cosmetic GMP), BPOM and other applicable regulatory requirements in each jurisdiction.
Separately, under the INVITRX collaboration the same brand and formulation assets are manufactured in the United States — at INVITRX’s facility, with INVITRX ingredients — and sold there. Indonesia and the United States are therefore two parallel “make locally, sell locally” markets for GENRÊVER, rather than export destinations for products made in Japan.
Population figures are public statistics. The Company does not provide revenue or market-share forecasts for any of these initiatives.
GENRÊVER brand site
Learn more
For photos, product details and the latest on GENRÊVER, visit the GENRÊVER brand site
www.genrever.com
Milestones and status
Initiative — Milestone — Status
GENRÊVER CLINIC (Jakarta) — Announcement and 6-K filing (July 29, 2026) — Completed
Premises secured — 213 m², Gandaria, South Jakarta — Completed
Interior construction — In progress
Preliminary subscription pricing (3 tiers) — Finalized (preliminary)
Permitting, staffing and opening (targeted by end of December 2026) — Planned
INVITRX (U.S.) — Memorandum of Agreement (July 30, 2026) — Completed
Initial GENRÊVER U.S. product line-up identified — Completed
Final formulation, scheduling, commercial arrangements; manufacturing (targeted within 2026) — In progress
PARVA (Indonesia) — Collaboration announced (August 10, 2026) — Completed
Two initial product candidates identified (UV cream; HA4 moisturizing gel) — Completed
Development, BPOM/halal preparation, production (targeted within 2026) — In progress
All targeted dates are subject to the conditions described above and in the Forward-Looking Statements section below.
Comment from the Chief Executive Officer
“During the past several weeks, we have progressed site development activities in Jakarta and continued product planning discussions with our manufacturing collaborators in the United States and Indonesia.” — Tomoki Nagano, Chief Executive Officer
Related Press release (September 4, 2026): INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives — [IR page link] Product Development Progress Update: Indonesia Cosmetics Collaboration with PT PARVA CANDELA — [link] INVITRX Collaboration Update: GENRÊVER — Made in the U.S., Sold in the U.S. — [link] August 10, 2026 — Strategic collaboration with PT PARVA CANDELA — [link] July 30, 2026 — Strategic collaboration with INVITRX — [link] July 29, 2026 — GENRÊVER CLINIC in Indonesia — [link]
About Instinct Bio
INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) is a biotechnology company focused on regenerative medicine, wellness-related technologies, and therapeutic platform development. Website: https://instinct-biot.com/
Forward-Looking Statements
This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated opening and operation of the Jakarta clinic and any subsequent clinics, expected subscription offerings and pricing, product development activities, potential manufacturing timelines, halal certification and other regulatory processes, potential export or expansion into other markets, and the Company’s collaborations with INVITRX and PARVA. These statements are based on current expectations and are subject to risks and uncertainties, many beyond the Company’s control, including construction delays, permitting and regulatory developments, product development outcomes, manufacturing and supply chain constraints, market conditions, the negotiation of definitive agreements, customer acceptance, and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. Actual results may differ materially, and readers are cautioned not to place undue reliance on these statements, which speak only as of the date hereof. Except as required by applicable law, the Company undertakes no obligation to update them. Third-party market data cited on this page are estimates of the respective sources and are provided for context only; the Company has not independently verified them and does not adopt them as forecasts.
Contact Information INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. Email: ir@instinct-bro.com Website: https://instinct-biot.com/ Sign up for email alerts on press releases, SEC filings and events at instinct-biot.com/investors.
Source Documents
Follow @BIOT_jp on X for company news and published IR updates.
